Bayer, J&J eye blockbuster supplemental OK for Xarelto; SetPoint raises $30M for bioelectronics

⇨ The anti-clot therapy Xarelto from Bayer and J&J may have a much brighter future now that researchers have posted its effect on preventing heart attacks and strokes among patients suffering from atherosclerosis. Already approved for use, analysts say the drug could now see its potential market more than double overnight with an approval in this indication, which could easily be worth well over a billion dollars in additional sales.

⇨ Valencia, CA-based SetPoint Medical has rounded up a $30 million D round for its bioelectronics work. NEA, Morgenthaler, Medtronic, Boston Scientific, Topspin, Action Potential Venture Capital and others were involved in the raise.

⇨ The FDA has granted a priority review for Genentech’s Gazyva, speeding a review for follicular lymphoma.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 48,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->